DSS’s Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant
07 June 2022 - 9:00PM
DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a
multinational company operating businesses within nine divisions
and strategically acquiring and developing assets to enrich the
value of its shareholders through calculated IPO spinoffs and a
parametric share distribution strategy, today announced Global
BioLife, Inc. (“Global BioLife”), a division of the Company’s
wholly owned subsidiary Impact BioMedical, was granted a patent
(No. 2020119933780) from the China National Intellectual
Property Administration (“CNIPA”) for 3F™, a Functional Fragrance
Formulation (3F™) technology that is effective as a mosquito
repellant through a fragrant compound derived from botanical oils.
This complements the corresponding U.S. patent granted (U.S.
11,246,310)
3F™ is an extremely effective mosquito
repellant. The repellant is believed to incapacitate two of the
three receptors that mosquitoes use to find sources of
nutrition.
“While existing mosquito repellants target only
the gustatory receptors in insects, 3F™ uses a multiple receptor
approach by targeting ionotropic, gustatory and olfactory receptors
in insects to provide a synergistic action to repel insects as well
as inhibit the ability of insects to detect and seek prey,” says
Daryl Thompson, Director of Scientific Initiatives at Global
BioLife and founder of advanced research company GRDG Sciences, LLC
(“GRDG”).
While 3F™ has far-reaching applications for
everyday life, the most important application could be saving
lives. According to the National Institutes of Health, mosquitos
are responsible for more than a million deaths each year because
they can host a variety of diseases including malaria, dengue, West
Nile yellow fever, Zika, chikungunya, and lymphatic filariasis.
“3F™ is an innovative solution for real-world
problems that can be integrated into a wide variety of everyday
products by major brands,” said Frank Heuszel, President of Impact
BioMedical. “The potential for this technology in the vast market
of China is immense, and we look forward to executing a licensing
and commercialization strategy around this product that drives
strong value for our shareholders while positively impacting
consumers in their everyday lives.”
The global mosquito repellant market was
estimated at $6.9 billion in 2021 and expected to reach $10.9
billion by the end of 2028, according to data from Zion Market
Research. China is a leading market globally for the sale of insect
repellant products, with an increasing demand for plant-based
insect repellants being a key driver of market growth in recent
years, according to GMA, a Shanghai-based consumer marketing
agency.
During the past year, Impact BioMedical has
laid the groundwork for a future that is focused on scientifically
tested, high-impact solutions to global problems that humans are
facing from food preservation to antibiotics to creating new ways
to develop medicines. Impact Biomedical and GRDG announced a U.S.
patent (US 10,966,424) allowance for 3F™DB in June 2021.
About Impact BioMedical,
Inc.Impact BioMedical drives mission-oriented research,
development, and commercialization of solutions for medical
advances in human wellness and healthcare. By leveraging technology
and new science with strategic partnerships, Impact BioMedical
provides advances in drug discovery for the prevention, inhibition,
and treatment of neurological, oncology and immuno-related
diseases. Other exciting technologies include a breakthrough
alternative sugar aimed to combat diabetes and functional fragrance
formulations aimed at the industrial and medical
industry. For more information on Impact BioMedical
visit http://impbio.com/.
About DSS, Inc.DSS is a
multinational company operating businesses within nine divisions:
Product Packaging, Biotechnology, Direct Marketing, Commercial
Lending, Securities and Investment Management, Alternative Trading,
Digital Transformation, Secure Living, and Alternative Energy. DSS
strategically acquires and develops assets to enrich the value of
its shareholders through calculated IPO spinoffs and a parametric
share distribution strategy. Since 2019, under the guidance of new
leadership, DSS has built the necessary foundation for achievable
growth through the formation of a diversified portfolio of
companies positioned to drive profitability in multiple high growth
sectors. These companies offer innovative, flexible, and real-world
solutions that not only provide mutual benefits for businesses and
their customers, but also create sustainable value and opportunity
for transformation.
For more information on DSS
visit http://www.dssworld.com.
Investor Contact:Dave Gentry, CEORedChip
Companies Inc.407-491-4498DSS@redchip.com
Safe Harbor DisclosureThis
press release contains forward-looking statements that are made
pursuant to the safe harbor provisions within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include, but are not limited to,
statements related to the Company's intended use of proceeds and
other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are
subject to risks and uncertainties that may cause actual results or
events to differ materially from those projected. These risks and
uncertainties, many of which are beyond our control, include: risks
relating to our growth strategy; our ability to obtain, perform
under and maintain financing and strategic agreements and
relationships; risks relating to the results of development
activities; our ability to attract, integrate and retain key
personnel; our need for substantial additional funds; patent and
intellectual property matters; competition; as well as other risks
described in the section entitled "Risk Factors" in the prospectus
and in our other filings with the SEC, including, without
limitation, our reports on Forms 8-K and 10-Q, all of which can be
obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect
management's current estimates, projections, expectations, and
beliefs. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions, or circumstances
on which any such statement is based, except as required by
law.
DSS (AMEX:DSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Jul 2023 to Jul 2024